SCHEMBL640482

SCHEMBL640482

S=c1[nH]cc(-c2cccc(C3CCOCC3)c2)[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
HDAC8 Q9BY41 1/20 0.39
NOTUM Q6P988 1/20 0.36
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
MCL1 Q07820 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
OPRL1 P41146 1/20 0.33
PIK3CD O00329 3/20 0.32
PRKAB2 O43741 3/20 0.32
PRKAG1 P54619 3/20 0.32
PRKAA2 P54646 3/20 0.32
PRKAA1 Q13131 3/20 0.32
PRKAG3 Q9UGI9 3/20 0.32
PRKAG2 Q9UGJ0 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639698 0.87 GFER (0.51) GFERKDM4EGAAHDAC8NOTUM
SCHEMBL638661 0.86 GFER (0.50) GFERKDM4EGAAHDAC8NOTUM
SCHEMBL640257 0.83 GFER (0.49) GFERKDM4EGAAHDAC8NOTUM
Morpholine SCHEMBL3636258 0.70 GFER (0.69) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL639462 0.69 KDM4E (0.53) GFERKDM4EGAAHDAC8NOTUM
SCHEMBL3341441 0.68 GFER (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL3341447 0.68 KDM4E (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL639362 0.68 GFER (0.61) GFERKDM4EGAAHDAC8ALDH1A1
SCHEMBL3344186 0.68 KDM4E (0.61) GFERKDM4EGAAHDAC8NOTUM
SCHEMBL638653 0.68 KDM4E (0.51) GFERKDM4EGAAHDAC8NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US claimed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US claimed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP claimed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO claimed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO claimed
US-8119674-B2 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2012-02-21 US disclosed
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-06-10 US disclosed
EP-2155693-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY Galderma Research & Development (FR) 2010-02-24 EP disclosed
WO-2008152331-A9 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2009-12-23 WO disclosed
WO-2008152331-A1 NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144814-A1 NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF TYR, TH, PAH GFER 2966/4885KDM4E 582/4885GAA 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.